Fairness opinionsProfessional Services2012

IntegraMed America acquired by Sagard Capital Partners: fairness opinion by Jefferies

Announced June 11, 2012 · One-step merger · All cash · DEFM14A filed August 20, 2012
Professional Services Vein / Fertility
Enterprise value
$178M
EV / LTM EBITDA
8.5x
EBITDA $20.9M · 7% margin
EV / LTM revenue
0.59x
revenue $303M
DCF discount rate
13.5%–14.5%
Perpetuity growth

Deal terms

ConsiderationAll cash
Price per share$14.05
Premium
Premium basis
StructureOne-step merger
Termination fee$5.1M
Reverse termination fee$8.5M
Go-shopNone
Outside date

Implied value per share by method vs. $14.05 offer

Selected companies — TEV / CY2012E Adjusted EBITDA $10.85 – $14.26
Selected companies — TEV / CY2013E Adjusted EBITDA $11.55 – $15.85
Precedent transactions — EV / LTM Adjusted EBITDA $12.52 – $15.61
Discounted cash flow $14.38 – $17.17
Premiums Paid Analysis (informational only) $13.84 – $17.51

Ranges as disclosed in the banker’s summary of analyses; the red line marks the per-share consideration.

Opinion of Jefferies to the target board

Delivered June 9, 2012 · Fee $2.0M ($1.0M contingent on closing)

Discounted cash flow assumptions

Discount rate13.5%–14.5%
Basisweighted average cost of capital
Terminal valuePerpetuity growth
Perpetuity growth1.0%–3.0%
Exit multiple
Projection period2012E-2016E
Projections usedinternal estimates of Company management (May 2012 updated forecasts)
Implied value per share$14.38–$17.17

Free cash flows calculated as adjusted EBITDA (stock-based comp treated as non-cash) less D&A, less taxes at an assumed 40.5% rate, plus D&A, less capex, less increases/plus decreases in working capital. Terminal value derived by applying perpetuity growth rates to CY2016 unlevered free cash flows adjusted to normalized levels.

Selected public companies (10)

Almost Family, Inc. · Amedisys, Inc. · AmSurg Corp. · Chemed Corporation · Gentiva Health Services Inc. · Hanger Orthopedic Group, Inc. · LHC Group, Inc. · Lincare Holdings Inc. · RadNet, Inc. · US Physical Therapy Inc.

MultiplePeer lowPeer medianPeer highRange appliedImplied per share
TEV / CY2012E Adjusted EBITDA4.5x5.5x7.7x 4.0x–6.0x $10.85–$14.26
TEV / CY2013E Adjusted EBITDA4.3x5.3x7.2x 3.5x–5.5x $11.55–$15.85

Selected precedent transactions (14)

DateTargetAcquirerMultiple
2011-11-04American Dental Partners, Inc.JLL Partners, Inc.
2011-07-29Allied Healthcare International Inc.Saga Group Ltd.
2011-04-07National Surgical Care, Inc.AmSurg Corp.
2011-03-03America Service Group Inc.Valitas Health Services, Inc.
2011-01-21NovaMed, Inc.Surgery Center Holdings, Inc.
2010-09-27NightHawk Radiology Holdings, Inc.Virtual Radiologic Corporation
2010-08-16Prospect Medical Holdings, Inc.Leonard Green & Partners, L.P.
2010-08-14Res-Care, Inc.Onex Corporation
2010-05-24Odyssey Healthcare, Inc.Gentiva Health Services Inc.
2010-04-05National Dentex CorporationGDC Holdings, Inc.
2010-01-24Critical Homecare Solutions Holdings, Inc.Bioscrip, Inc.
2008-06-19Apria Healthcare Group Inc.The Blackstone Group L.P.
2008-02-19TLC Health Care Services, Inc.Amedisys, Inc.
2007-04-24Symbion, Inc.Crestview Partners, L.P.
MultipleLowMedianHighRange appliedImplied per share
EV / LTM Adjusted EBITDA5.2x7.6x9.3x 5.5x–7.5x $12.52–$15.61

Other analyses

AnalysisSummaryImplied per share
Premiums Paid Analysis (informational only)Premiums paid in selected North American healthcare service company transactions announced January 1, 2008 to June 8, 2012 with transaction values of $50 million to $1.0 billion; selected premium range of 24% to 56% applied to closing price of common shares on March 12, 2012 (last trading day before news reports the Company was exploring a sale).$13.84–$17.51

Aggregate fee of $2.0 million for financial advisory services, of which a portion was payable upon delivery of Jefferies' opinion and $1.0 million is payable contingent upon completion of the merger; plus expense reimbursement and indemnification.

3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.
See the Valuation database →

Management projections

Projection yearYear 1Year 2Year 3Year 4CAGR
Revenue$338M$380M$427M$480M12.4%
Revenue growth11.6%12.4%12.5%12.3%
EBITDA$26.3M$33.1M$41.6M$51.0M24.7%
EBITDA growth25.6%25.9%25.7%22.6%
EBITDA margin8%9%10%11%
Implied EV / EBITDA6.8x5.4x4.3x3.5x

Year-1 growth is against LTM at announcement ($303M revenue, $20.9M EBITDA); later years are year over year.

Management prepared financial forecasts for 2011E-2016E showing revenues growing from $270.3 million (2011E) to $479.7 million (2016E) and adjusted EBITDA from $17.5 million to $51.0 million. These were updated in May 2012 for actual 2011 and Q1 2012 results, producing a 2012E-2016E case with revenues of $302.8 million (2012E) to $479.7 million (2016E), adjusted EBITDA of $20.8 million to $50.9 million, and free cash flow of $1.9 million to $22.8 million; the updated forecasts were used by Jefferies. A terminal year free cash flow of $24.6 million was also calculated reflecting steady-state operations excluding certain one-time 2016 capital expenditures.

Process notes

Going-private cash merger with Sagard Capital Partners affiliate; Jefferies was the sole financial advisor and delivered its opinion to the full board (no special committee described). The opinion addressed fairness to holders other than Sagard and its affiliates. Certain stockholders (IAT, Wilshire and Mr. Kellogg) entered into voting arrangements terminable upon a superior all-cash proposal of at least $16.50 per share. Target may also reimburse Buyer expenses up to $2,119,203, credited against the $5,086,087 termination fee; Sagard guaranteed Buyer's $8,476,812 reverse termination fee subject to that cap.

Other Professional Services fairness opinions

All Professional Services opinions → · Jefferies opinions